Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis

Diego Sangiorgi¹
Maurizio Benucci²
Carmela Nappi³
Valentina Perrone¹
Stefano Buda¹
Luca Degli Esposti¹

¹Clicon S.r.l., Health, Economics and Outcomes Research, Ravenna, ²Unit of Rheumatology, S. Giovanni di Dio Hospital, Florence, ³Bristol Myers Squibb S.r.l., Rome, Italy

Objectives: The use of biologic agents has revolutionized the management of rheumatoid arthritis (RA) in the past 2 decades. These biologic agents directly target molecules and cells involved in the pathogenesis of RA. The purpose of this study was to assess the usage of biologic agents in terms of persistence to treatment, dose escalation, and consumption of health care resources (hospitalizations, drugs, and outpatients service) in the real clinical practice in naïve patients with RA.

Methods: We conducted a real-world, retrospective, observational cohort study based on data obtained from administrative databases of three Local Health Units in Italy. The population included adults diagnosed with RA who had at least one prescription between January 1, 2009 and December 31, 2011, for a biologic that was approved for treatment of RA. The patients were followed for 12 months after enrollment. The clinical characteristics of the patients enrolled in this study were also investigated in the 1-year period before the index date. The main and secondary endpoints were evaluated only in biologic-naïve patients without switches. The overall health care costs for patients were evaluated.

Results: A total of 594 patients met the study criteria (mean age 53.5±13.5, female:male ratio =3:1). Thirty-nine percent received etanercept, 25% adalimumab, 14% infliximab, 10% abatacept, 9% tocilizumab, and 3% golimumab. After 1 year of observation, patients showed similar use of other RA-related medication. For the naïve patients without switches, the persistence levels were: 78% for etanercept, 72% for tocilizumab, 71% for adalimumab, 69% for infliximab, and 64% for abatacept. For all agents, dose escalation was 21.4% for infliximab, 11.5% for adalimumab, 5.6% for abatacept, 4% for tocilizumab, and 3.8% for etanercept. The annual costs per treated patients were €12,803 for adalimumab, €11,924 for etanercept, €11,830 for tocilizumab, €11,201 for infliximab, and €10,943 for abatacept.

Conclusion: The role of biologic therapies in the treatment of RA continues to evolve; our study reflects real-world drug utilization data in adult patients with RA. These observations could be used by decision makers to support formulary decisions, although further research is needed using a larger sample to validate these results.

Keywords: rheumatoid arthritis, biologic agents, real-world data

Introduction

Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease of unknown etiology affecting ~1% of the world population.¹,² The health-related quality of life in patients with RA is significantly reduced by pain, fatigue, loss of bodily function for progressive destruction of joint tissue, and a heavy economic burden associated with disease progression.
According to the European League Against Rheumatism recommendations, several treatment options are available for patients with RA. Medications for RA include nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic therapies.

The development of biologic agents during the last few decades has revolutionized the treatment of RA, improving outcomes for patient refractory or intolerant to conventional treatment and, in some cases, inducing clinical remission. Biologic agents are recommended for use in patients with active RA who have poor response or intolerance to traditional DMARDs. According to the last European recommendations, biologic agents can be administered for synthetic DMARD-naïve patients with unfavorable prognostic signs, including very active disease or early structural damage. The major targets of these biologic therapies include cytokines, immune cells, and some co-stimulatory molecules. The biologics licensed for use in this indication are tumor necrosis factor-α antagonists (four given subcutaneously: adalimumab, certolizumab-pegol, etanercept, and golimumab; and infliximab, given as intravenous infusions), the interleukin-6-receptor antagonist tocilizumab, the anti-B-cell agent rituximab, and the interleukin-1 inhibitor anakinra. All these biologic agents have been proven effective in alleviating the symptoms and in slowing structural disease progression in patients with RA and have comparable safety profiles. These agents differ in their routes of administration, dosage, and dose schedules; however, none of these biologics is clearly preferable to the others, since the efficacy and safety profiles were similar in several meta-analyses and a few head-to-head trials.

Unfortunately, these agents are not universally effective. Previous studies have shown that some patients require an upward dose adjustment or shortened dose interval to achieve or maintain a clinical response; for patients who are not likely to benefit from intensified therapy, clinicians will often switch to another biologic class with a different mechanism of action.

Observational studies have indeed reported comparable effectiveness between biologic drugs in clinical practice, but differences in utilization or in the total cost of care. Considering that the use of biologic agents is associated with significant costs, an important issue in the face of limited health care resources, to document the information of real-life practice could enhance the decision-making process in the management of RA patient.

The primary objective of the present study was to assess the drug usage in naïve patients with RA in terms of therapeutic strategy used, the route of administration of the therapeutic strategy (eg, intravenous or subcutaneous), persistence, dose escalation, and co-medication related to RA. The second objective was to estimate the total cost per patient with RA treated with biologics—drug treatment, diagnostic services, specialist visits, and hospital stays—in patients with RA.

Methods

Data source

The study was conducted using administrative databases of three Italian Local Health Units (LHU) in Campania (LHU Caserta), Lombardy (LHU Bergamo), and Lazio (LHU Roma D).

We used the Health-Assisted Subjects Database, containing patients’ demographic data; Territorial Pharmacy Database, providing information for each medication prescription, such as the prescribing physician’s number, the Anatomical Therapeutic Chemical code of the drug purchased, the number of packages, the number of units per package, the dosages, the unit cost per package, and the prescription date; Hospital Discharge Database, which includes all hospitalization data with the discharge diagnosis codes classified according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM); and the Ambulatory Care Specialist, which records outpatient specialist services (visits, laboratory tests, diagnostic tests) provided to the patient, such as the type of visit and the date of the visit. These administrative databases are complete, include validated data, and have been used in previous epidemiologic studies. The Italian Ministry of Health defined these archives as 100% complete and 95% accurate. In compliance with privacy laws, the patients’ identification code was encrypted and the individuals/bodies involved in processing of the data for the purposes of the analysis were blinded to the identification of patients. The patient code in each database permitted electronic linkage between all databases. In order to guarantee patient privacy, each subject was assigned an anonymous univocal numeric code. No identifiers related to patients were provided to the researchers. The LHU Ethics Committees approved the study.

Cohort definition

The study was a retrospective cohort study that included all patients (≥18 years old) with a diagnosis of RA between January 1, 2009 and December 31, 2011 (enrollment period). The RA diagnosis was retrieved from hospitalization (ICD-9-CM code 714) or specific exemption code.
The date of the first prescription of biologic agents (i.e., abatacept [Orencia®], adalimumab [Humira®], etanercept [Enbrel®], golimumab [Simponi®], infliximab [Remicade®], and tocilizumab [RoActemra]) in RA patients was defined as the “index date”, which represents the enrollment date of the individual patient, who was then followed for 1 year (“follow-up”). Anakinra [Kineret®] and certolizumab pegol [Cimzia®], as well as rituximab [Mabthera] were not included as index drugs in this analysis due to insufficient sample size. The clinical characteristics of the patients enrolled in this study were also investigated in the 1-year period before the index date. Naïve patients were defined as those who had no prior biologic agents prescription filled during the 1 year preceding the enrollment date.

The presence of previous use of DMARDs, antibiotics, or pain medications was also evaluated. Hospitalizations related to RA were identified by ICD-9-CM codes (primary or accessory diagnosis). The level of disease severity was measured using the MedStat Disease Staging Software®, which classifies the pathologies on the basis of their complications (stage 1, no complications; stage 2, local complications; stage 3, complications to multiple sites or systemic complications). Comorbidities were measured using the Charlson Comorbidity Index (CCI), which is defined as the sum of weights related to each condition (i.e., myocardial infarction, cancers, diabetes, ulcer) identified through treatments and hospitalizations. All comorbidities were evaluated in the 1-year period before the index date; the CCI score reflects a patient’s overall health status. This methodology has been widely used as a way to compare disease severity in retrospective analyses when data are unavailable.

According to the biologic therapeutic strategy used at the index date, naïve patients without switches were characterized according to usage of RA-related co-medication, persistence of treatments, dose escalation and outpatient visit, and RA-related hospitalization. Patients transferred to another LHU during the whole observation period (previous year and follow-up period) were excluded from analysis.

Patients were classified as persistent if they were still on treatment with the index drug during the last 3 months of observation. Dose escalation was evaluated as the change in the average dose prescribed between two following prescriptive intervals during the 12 months of observation. Dose escalation was defined as having two consecutive prescriptions with an average weekly dose 30% greater than the initial average weekly dose, according to previously published methods. To take into account the induction phase, dose escalation was identified following the third infusion; patients who had at least five infusions were included.

Cost analysis
Cost of illness was evaluated in biologic-naïve patients without switches after the index biologic date. Drug costs were evaluated using the National Health Service purchase price. Hospitalization costs were determined using the Diagnosis-Related Group tariff; these costs were related to RA main, secondary, or other diagnosis of hospitalizations. Other inherent hospitalization considered for disease staging were uveitis, fusion of metacarpophalangeal-interphalangeal joint spaces, carpal tunnel syndrome, anemia, Felty’s syndrome, pneumoconiosis, interstitial fibrosis, cardiac conduction abnormalities, pericarditis, cardiomyopathy, vasculitides, amyloidosis, congestive heart failure, respiratory failure. The cost of instrumental and laboratory tests was defined according to the tariffs applied by the Lombardy, Campania, and Lazio regions. Administration costs were included in the hospitalization costs for intravenous biologics. Subcutaneous agents were self-administered and, thus, no administration costs were considered for this route of administration. Mean annual total health care costs were estimated separately for different biologic treatments. The cost analysis was conducted from the perspective of the National Health Service. The currency reference used was the Euro (€).

Statistical analysis
Continuous variables were reported as mean and standard deviation (median and range as appropriate), whereas categorical variables were expressed as numbers and percentages. When comparisons were made, groups were assessed and compared using the Student’s t-test. Qualitative variables were expressed as absolute and relative frequencies. To control for confounding factors, we included in the model factors including age, sex, CCI, coexisting illnesses, and drug used; the analysis was conducted separately for naïve and established patients.

The P-values <0.05 were considered to be statistically significant, and all statistical analyses were conducted using SPSS statistical software for Windows, version 18.0 (SPSS Inc., Chicago, IL, USA).

Results
Of the total population of 2,100,000 subjects ≥18 years, patients available for analysis after applying the inclusion criteria were 594 (3 per 10,000 beneficiaries). Mean (SD) patient age at the index date was 53.5 ± 13.5 years. The majority of patients were female with a ratio of women to men of 3:1.
Patients’ characteristics and prior health care resources utilization are summarized in Table 1. The number and proportion of patients who received each index biologic were (in decreasing order): etanercept, 229 (39%); adalimumab, 150 (25%); infliximab, 82 (14%); abatacept, 62 (10%); tocilizumab, 54 (9%); and golimumab, 17 (3%) (Table 1). Golimumab was originally considered for the analysis, but due to the small sample size future analyses will be necessary to validate and confirm its data; therefore, golimumab was excluded from subsequent analyses. Patients who used other RA-related medication during the follow-up period are shown in Figure 1.

In case of the naïve patients without switches, the persistence rates for each biologic agent were: 78% for etanercept, 72% for tocilizumab, 71% for adalimumab, 69% for infliximab, and 64% for abatacept (Figure 2). Figure 3 shows the proportion of patients who underwent dose escalation during the period of study; dose escalation was 21.4% for infliximab, 11.5% for adalimumab, 5.6% for abatacept, 4% for tocilizumab, and 3.8% for etanercept. Among naïve patients without switches, the rates of hospitalization at 12 months of follow-up are summarized in Figure 4. Annual costs among all patients for each treatment was €12,803 for adalimumab, €11,924 for etanercept, €11,830 for tocilizumab, €11,201 for infliximab, and €10,943 for abatacept (Figure 5).

**Table 1** Demographic characteristics

<table>
<thead>
<tr>
<th></th>
<th>Abatacept (n=62; 10%)</th>
<th>Adalimumab (n=150; 25%)</th>
<th>Etanercept (n=229; 39%)</th>
<th>Golimumab (n=17; 3%)</th>
<th>Infliximab (n=82; 14%)</th>
<th>Tocilizumab (n=54; 9%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean ± SD</td>
<td>53.1±12.7</td>
<td>55.3±13.2</td>
<td>52.6±13.8</td>
<td>47.4±13.1</td>
<td>54.4±12.7</td>
<td>53.5±14.2</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>44 (71.0)</td>
<td>119 (79.3)</td>
<td>174 (76.0)</td>
<td>12 (70.6)</td>
<td>58 (70.7)</td>
<td>36 (66.7)</td>
</tr>
<tr>
<td>Charlson Comorbidity Index, mean ± SD</td>
<td>2.7±1.9</td>
<td>2.3±1.7</td>
<td>2.3±1.5</td>
<td>3.3±2.5</td>
<td>2.7±1.4</td>
<td>2.4±1.2</td>
</tr>
</tbody>
</table>

**Pre-index concomitant medication use**

<table>
<thead>
<tr>
<th></th>
<th>DMARD, n (%)</th>
<th>Antibiotics, n (%)</th>
<th>Pain medications, n (%)</th>
<th>Biologic-naïve patients, n</th>
<th>Patients without switches, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMARD, n (%)</td>
<td>55 (88.7)</td>
<td>82 (54.7)</td>
<td>98 (65.3)</td>
<td>54</td>
<td>38</td>
</tr>
<tr>
<td>Antibiotics, n (%)</td>
<td>115 (76.7)</td>
<td>130 (56.8)</td>
<td>156 (68.1)</td>
<td>95</td>
<td>84</td>
</tr>
<tr>
<td>Pain medications, n (%)</td>
<td>77.7</td>
<td>12 (70.6)</td>
<td>15 (88.2)</td>
<td>137</td>
<td>125</td>
</tr>
<tr>
<td>Biologic-naïve patients, n</td>
<td>17 (100.0)</td>
<td>15 (88.2)</td>
<td>17</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>Patients without switches, n</td>
<td>74 (90.2)</td>
<td>49 (59.8)</td>
<td>64 (78.0)</td>
<td>39</td>
<td>35</td>
</tr>
</tbody>
</table>

**Abbreviation:** DMARD, disease-modifying antirheumatic drugs.

Discussion

This study provides an evaluation of drug utilization and costs in a cohort of RA patients treated with biologic agents. Differences in the route of administration and flexibility of dosing of these agents may result in different medication use profiles (eg, persistence, discontinuation, dose escalation, switching to a new biologic RA drug, and usage of RA-related co-medications) in real-life clinical setting. In the last few years, several network meta-analyses tried to compare biologic drugs used in RA. Consistent with previous studies and in line with the recommendations of Italian Society of Rheumatology pertaining to RA treatment, we found that etanercept, adalimumab, followed by infliximab were the most commonly used. There are variations in the usage of biologic agents among countries based on licensing, local guidelines, and policies.

![Figure 1](https://example.com/figure1.png)

**Figure 1** Concomitant medication use, follow-up period.

**Abbreviation:** DMARD, disease-modifying antirheumatic drugs.
Health care resources for patients with rheumatoid arthritis

The various structures of health care systems in different countries make comparisons between studies difficult. In addition, access to biologic drugs differs among countries. Glucocorticoids as well as nonsteroidal anti-inflammatory drugs and DMARDs are among the most important drugs used in the routine clinical practice and still play a decisive role in the management of diverse rheumatic conditions. Our patients showed similar treatment patterns as reported in a recent study. After 1 year of observation, a higher level of persistence was observed in the etanercept cohort with respect to those treated with other biologic agents. These results, however, must be kept with caution due to the differences of the sample size among the various analyzed biologics.

Taking therapies as prescribed is crucial for the achievement of the goals of RA treatment, which are to induce remission, to prevent joint damage and destruction, to prevent disability, and to improve quality of life. Studies of persistence with biologic therapy have yielded varying results. Higher persistence with infliximab has been reported in a US pharmacy database analysis, while some data from European registries showed the lowest persistent with infliximab. In contrast, data from a Danish registry showed that persistence was the highest with etanercept and the lowest with infliximab, with 56% and 41% of patients, respectively, who persisted in the therapy at 2 years. This analysis indicated that dose escalation was less frequent among patients treated with etanercept (3.8%) and abatacept (5.6%) compared with infliximab (21.4%). The adalimumab dosage increase rate was 11.5%; our results are in contrast with the Italian recommendations (at time of completion of the literature analysis), where the incremental dose of adalimumab does not seem to be helpful on clinical ground.

The results presented here are consistent with those reported from other published studies. It is important to note that the variation estimates in previous research may be due to the method of calculating dose escalation.

During the observation period, patients requiring incremental dose were the same patients with the highest rate of
Hospitalizations. It may be explained by previous investigations\(^5\,^2\) that show the association between dose escalation and high risk of adverse event despite only a few studies to have evaluated the effect of dose escalation on clinical outcomes\(^5\,^3,^4\).

Our analysis also evaluated the cost of management of RA patients treated with biologic agents in a real-world setting. Several studies in the clinical practice setting have found relationship between dose escalation and significant cost increase\(^1\,^7,^2^2,^4^3,^4^5,^5^2\). Previous studies have suggested that patients with higher persistence rates have lower medical (non-pharmacy) costs, suggesting that they used fewer medical resources, which may indicate a positive effect on quality life\(^2^3\). Although our results showed that persistence and escalating the dose of treatment have influenced the overall health care cost, it remains difficult to compare these data with other studies because few analyses included all biologic agents approved for RA treatment and further research is needed using a larger sample to validate these results. Additionally, our findings showed that a consistent percentage of patients underwent dose escalation; because of this, we used the persistence rates to explore the discontinuation of medication rather than the adherence rates, a method influenced by dose-escalating treatments.

In this analysis, the cohort of patients reflected clinical-practice situations, but the results must be interpreted in the context of several limitations. Comparisons between biologics were complicated by large differences in sample size between the most commonly used and the other biologics. Based on the study time period, there were an insufficient number of patients on biologic therapies (eg, anakinra, adalimumab, etanercept, infliximab, tocilizumab, and abatacept).

**Figure 4** Hospitalizations, naive patients without switches.

**Note:** "Other inherent hospitalizations considered for disease staging (uveitis, fusion of metacarpophalangeal interphalangeal joint spaces, carpal tunnel syndrome, anemia, Felty’s syndrome, pneumoconiosis, interstitial fibrosis, cardiac conduction abnormalities, pericarditis, cardiomyopathy, vasculitides, amyloidosis, congestive heart failure, and respiratory failure)."

**Abbreviation:** RA, rheumatoid arthritis.

**Figure 5** Cost of illness, naïve patients without switches.

**Abbreviations:** DMARD, disease-modifying antirheumatic drugs; RA, rheumatoid arthritis.
certolizumab pegol, golimumab, rituximab) for 12 or more months to include in the analysis.

Because this was a retrospective analysis of administrative databases, important clinical information such as severity of disease, clinical response to treatment, clinical decision drivers to administer a given biologic agent (ie, high-risk patient), and the reason of switch or dose escalation is not captured. The major limitation is the lack of clinical severity at baseline, leading us to conclude that channeling bias could have a major contribution to all of the findings. The absence of weight information increases the difficulty in capturing dose for infusion-administered drugs such as infliximab. The choice of different biologic agents is usually based on their safety profile, route of administration, costs, and patient profiles.

Conclusion
Despite our limitations and that the head-to-head comparisons were difficult because the clinical status of subjects enrolled were not available from the administrative database, our analysis provides an illustration of biologic therapy utilization in adult patients with RA, these observations could be used by decision makers to support therapeutic decisions.

Acknowledgments
We would like to thank Dr Rossana Piccinelli and Dr Francesca Atzeni (LHU di Bergamo), Dr Alessandra Blasi and Dr Eugenia Pagonzzi (Area Politiche del Farmaco LHU Roma D), LHU Caserta. The abstract of this paper was presented at the International Society for Pharmaco-economics and Outcomes Research (ISPOR) 17th Annual European Congress, Amsterdam (the Netherlands) 2014, named “Drug usage analysis and health care resources consumption in patients with rheumatoid arthritis as a poster presentation with interim findings”. The poster’s abstract was published in “Poster Abstracts” in 17:7, PMS 6 journal Value in Health.55 Manuscript development was supported by unconditional funding from Bristol-Myers Squibb.

Author contributions
All authors contributed toward data analysis, drafting, and revising the paper and agree to be accountable for all aspects of the work.

Disclosure
CN is employee of Bristol-Myers Squibb. The authors report no other conflicts of interest in this work.

References


